FIELD: medicine.
SUBSTANCE: invention represents an encapsulated liposomal antiviral agent based on human interferon alpha-2b for vaginal application, characterised by the fact that each capsule is made in the form of a hollow coating, which encloses a powder excipient and liposomes distributed in the excipient, and sodium alginate, a water-soluble polymer gel former; the excipient consists of lactose, sodium chloride, 12-aqueous disodium hydrogen phosphate and sodium dihydrogen phosphate, whereas each of the liposomes represents a hollow coating containing lecithin, cholesterol and alpha-tocopherol, and a nucleus inside the coating and containing recombinant human interferon alpha-2; the ingredients of the agents are taken in a certain ratio, mg.
EFFECT: maintaining the storage activity of recombinant human interferon alpha-2 and prolonged action in vaginal application.
2 cl, 3 dwg, 6 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LIPOSOMAL PERORAL ANTIVIRAL TREATMENT-AND-PROPHYLACTIC AGENT ON BASIS OF HUMAN INTERFERON ALPHA | 2008 |
|
RU2361572C1 |
| METHOD FOR PRODUCING LIPID MIXTURE AND LIPOSOMAL ORAL ANTIVIRAL THERAPEUTIC AND PROPHYLACTIC AGENT USING SAID LIPID MIXTURE | 2020 |
|
RU2746320C1 |
| COMPOSITION OF AQUEOUS SOLUTION OF RECOMBINANT HUMAN INTERFERON ALPHA-2 FOR RECTAL ADMINISTRATION | 2014 |
|
RU2564951C1 |
| METHOD FOR TREATING ACUTE HEPRETIC STOMATITIS IN CHILDREN | 2011 |
|
RU2444372C1 |
| LIPOSOMAL AGENT FOR TREATING CHRONIC ATROPHIC GASTRITIS | 2019 |
|
RU2724021C1 |
| COMPLEX ACTION MEDICATION AND METHOD OF ITS PRODUCTION | 2012 |
|
RU2519553C1 |
| LIPOSOMAL ANTIVIRAL DRUG FOR ORAL USING | 1996 |
|
RU2123328C1 |
| METHOD OF PRODUCING LIPOSOMAL COSMETIC SERUM IN DRY LYOPHILIZED FORM FOR FACE, NECK AND CLEAVAGE SKIN CARE | 2023 |
|
RU2825130C1 |
| COSMETIC FACE MASK FILM FOR FACE SKIN CARE WITH VITAMINS IN LIPOSOMES | 2019 |
|
RU2715231C1 |
| METHOD OF OBTAINING DRY LIPOSOMAL PREPARATIONS (VERSIONS) | 2009 |
|
RU2437649C2 |
